{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:17:22Z","timestamp":1788023842796,"version":"build-2784847793"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This meta-analysis will evaluate the risk of hepatitis B reactivation in patients treated with ustekinumab for inflammatory bowel disease and psoriasis. We aim to determine the true incidence of this adverse event, reconcile discrepancies in reported reactivation rates, and elucidate the associated risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a rigorous systematic review adhering to established guidelines. Major databases like MEDLINE, Google Scholar, CENTRAL, and ClinicalTrials.gov were searched. Studies involving patients with documented hepatitis B infection undergoing ustekinumab therapy were included. Patients receiving concurrent antiviral medications were excluded. To account for potential underreporting, studies without reactivation events or with sample sizes \u22653 were also considered by using generalized linear mixed models and Clopper\u2013Pearson confidence intervals. This review was prospectively registered in PROSPERO (CRD42023418130).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We analyzed data from nine studies involving 104 hepatitis B virus (HBV)-infected patients. The pooled HBV reactivation (HBVr) incidence among hepatitis B surface antigen-positive patients was 10% [95% confidence interval (CI): 0\u201331%], with low heterogeneity (<jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u20057.13%, <jats:italic toggle=\"yes\">\u03c4<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u20050.4) and a nonsignificant <jats:italic toggle=\"yes\">Q<\/jats:italic>-statistic (<jats:italic toggle=\"yes\">Q<\/jats:italic>\u2005=\u20055.38, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.37). For the occult HBV-infected patients, the pooled HBVr incidence was 3% (95% CI: 0\u201311%), with no heterogeneity (<jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u20050%, <jats:italic toggle=\"yes\">\u03c4<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u20050.0) and a nonsignificant <jats:italic toggle=\"yes\">Q<\/jats:italic>-statistic (<jats:italic toggle=\"yes\">Q<\/jats:italic>\u2005=\u20052.7, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.61). The reactivation rates showed high consistency across studies, with no significant difference between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>While our data suggest lower HBVr risk with ustekinumab, confirmation is needed due to limited sample size and retrospective design.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002863","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T21:00:31Z","timestamp":1733173231000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The incidence of hepatitis B reactivation in patients receiving ustekinumab: a systematic review and proportional meta-analysis"],"prefix":"10.1097","volume":"37","author":[{"given":"Marouf M.","family":"Alhalabi","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Damascus Hospital, Damascus, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Almokdad","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Damascus Hospital, Damascus, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"R1-20241202","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20241202","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease.","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R3-20241202","first-page":"1498","article-title":"Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab.","volume":"11","author":"Opel","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"R4-20241202","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial.","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R5-20241202","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","article-title":"Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension.","volume":"16","author":"Abreu","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R6-20241202","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.12646","article-title":"Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).","volume":"170","author":"Paul","year":"2014","journal-title":"Br J Dermatol"},{"key":"R7-20241202","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long\u2010term efficacy of ustekinumab in patients with moderate\u2010to\u2010severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.","volume":"166","author":"Kimball","year":"2012","journal-title":"Br J Dermatol"},{"key":"R8-20241202","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis through 5 years in Crohn\u2019s disease and 4 years in ulcerative colitis.","volume":"18","author":"Ghosh","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"R9-20241202","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1093\/ecco-jcc\/jjx180.737","article-title":"P610 risk of active hepatitis B and C infections in the phases 2 and 3 clinical trial programmes for ustekinumab.","volume":"12","author":"Gish","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R10-20241202","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R11-20241202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"R12-20241202","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R13-20241202","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/apt.17155","article-title":"Meta-analysis: hepatitis B reactivation in patients receiving biological therapy.","volume":"56","author":"El Jamaly","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-20241202","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion.","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol"},{"key":"R15-20241202","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/apt.17682","article-title":"Letter: incidence of hepatitis B virus reactivation in patients with psoriasis treated with cytokine inhibitors.","volume":"58","author":"Kuo","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-20241202","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"key":"R17-20241202","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute Guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"R18-20241202","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies.","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"key":"R19-20241202","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"R20-20241202","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jrsm.1378","article-title":"Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources.","volume":"11","author":"Gusenbauer","year":"2020","journal-title":"Res Synth Methods"},{"key":"R21-20241202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study.","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst Rev"},{"key":"R22-20241202","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews.","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"R23-20241202","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R24-20241202","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of hepatitis B virus: a review of clinical guidelines.","volume":"15","author":"Myint","year":"2020","journal-title":"Clin Liver Dis"},{"key":"R26-20241202","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool.","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"R29-20241202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Soft"},{"key":"R31-20241202","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"R32-20241202","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.","volume":"41","author":"Hayashi","year":"2014","journal-title":"J Dermatol"},{"key":"R33-20241202","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ad.2015.01.010","article-title":"Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database.","volume":"106","author":"Sanz-Bueno","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"R34-20241202","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab.","volume":"38","author":"Sw","year":"2018","journal-title":"Clin Drug Investig"},{"key":"R35-20241202","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/bjd.17444","article-title":"Ustekinumab use in patients with severe psoriasis co\u2010infected with hepatitis B and\/or C.","volume":"180","author":"Siegel","year":"2019","journal-title":"Br J Dermatol"},{"key":"R36-20241202","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ibd\/izad032","article-title":"Risk of tuberculosis and hepatitis B reactivation in patients with Crohn\u2019s disease on ustekinumab: a Nationwide Real-World Study.","volume":"30","author":"Liu","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R37-20241202","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/09546634.2018.1430301","article-title":"Safety of biologic agents for psoriasis in patients with viral hepatitis.","volume":"29","author":"AlMutairi","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"R38-20241202","doi-asserted-by":"crossref","first-page":"561","DOI":"10.5152\/tjg.2018.18032","article-title":"Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity.","volume":"29","author":"Solay","year":"2018","journal-title":"Turk J Gastroenterol"},{"key":"R39-20241202","doi-asserted-by":"crossref","first-page":"e15274","DOI":"10.1111\/dth.15274","article-title":"Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection.","volume":"35","author":"K\u0142ujszo","year":"2022","journal-title":"Dermatol Ther"},{"key":"R40-20241202","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection.","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"R41-20241202","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s10620-020-06725-1","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab-containing treatment.","volume":"66","author":"Kuo","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R42-20241202","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/1756-185X.13582","article-title":"Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation.","volume":"22","author":"Chen","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R43-20241202","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/1756-185X.13401","article-title":"Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.","volume":"22","author":"Watanabe","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R44-20241202","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jvh.13410","article-title":"Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.","volume":"28","author":"Rodr\u00edguez-Tajes","year":"2021","journal-title":"J Viral Hepat"},{"key":"R45-20241202","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jmii.2017.04.002","article-title":"Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis \u2013 a three-year study in Taiwan.","volume":"52","author":"Lin","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"R46-20241202","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3349\/ymj.2018.59.3.452","article-title":"Safety of Tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: data from real-world experience.","volume":"59","author":"Ahn","year":"2018","journal-title":"Yonsei Med J"},{"key":"R47-20241202","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study.","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"R48-20241202","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2468-1253(22)00201-1","article-title":"Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis.","volume":"7","author":"Im","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R49-20241202","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjd.12613","article-title":"Hepatitis B virus reactivation after ustekinumab treatment: reply from authors.","volume":"170","author":"Tsai","year":"2014","journal-title":"Br J Dermatol"},{"key":"R50-20241202","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R51-20241202","doi-asserted-by":"crossref","first-page":"921084","DOI":"10.3389\/fphar.2022.921084","article-title":"Hepatitis B virus reactivation and mycobacterial infections associated with ustekinumab: a retrospective study of an international pharmacovigilance database.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T21:00:43Z","timestamp":1733173243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002863","relation":{},"ISSN":["0954-691X","1473-5687"],"issn-type":[{"value":"0954-691X","type":"print"},{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}